atezolizumab,adagrasib
roche,mirati
['nsclc', 'impower,10', 'sclc', 'ca,022,i', 'ca,022,1', 'adagrasib', 'atezo', 'impower010', 'thoracic', 'porter', 'award', ' ave ', 'impower,150', 'biomarker', 'selection,(-selectionlte),(-selection lte),(-selection-lte)', 'lung', 'camrelizumab', 'marker ']
#esmoimmuno22: exploratory analysis of impower010 confirms that #ctdna is prognostic for adjuvant atezolizumab in #nsclc, but that its predictive value is still uncertain 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.